Shirong Cai

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Breast Cancer Risk

Top Venues

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Guang Lei, Chao Mao, Amber D Horbath, Yuelong Yan, Shirong Cai, Yao Jun, Yan Jiang, Mingchuang Sun, Xiaoguang Liu, Jun Cheng, Zhihao Xu, Hyemin Lee, Qidong Li, Zhengze Lu, Li Zhuang, Mei-Kuang Chen, Anagha Alapati, Timothy Anthony Yap, Mien-Chie Hung, Mingjian James You, Helen Piwnica-Worms, Boyi Gan
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer discovery 14 (8) (2024)
Guang Lei, Chao Mao, Amber D Horbath, Yuelong Yan, Shirong Cai, Yao Jun, Yan Jiang, Mingchuang Sun, Xiaoguang Liu, Jun Cheng, Zhihao Xu, Hyemin Lee, Qidong Li, Zhengze Lu, Li Zhuang, Mei-Kuang Chen, Anagha Alapati, Timothy Anthony Yap, Mien-Chie Hung, Mingjian James You, Helen Piwnica-Worms, Boyi Gan
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer discovery 14 (8) (2024)
Guang Lei, Chao Mao, Amber D Horbath, Yuelong Yan, Shirong Cai, Yao Jun, Yan Jiang, Mingchuang Sun, Xiaoguang Liu, Jun Cheng, Zhihao Xu, Hyemin Lee, Qidong Li, Zhengze Lu, Li Zhuang, Mei-Kuang Chen, Anagha Alapati, Timothy Anthony Yap, Mien-Chie Hung, Mingjian James You, Helen Piwnica-Worms, Boyi Gan
BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer discovery (2024)
Guang Lei, Chao Mao, Amber D Horbath, Yuelong Yan, Shirong Cai, Yao Jun, Yan Jiang, Mingchuang Sun, Xiaoguang Liu, Jun Cheng, Zhihao Xu, Hyemin Lee, Qidong Li, Zhengze Lu, Li Zhuang, Mei-Kuang Chen, Anagha Alapati, Timothy Anthony Yap, Mien-Chie Hung, Mingjian James You, Helen Piwnica-Worms, Boyi Gan
BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers. Cancer discovery (2024)
Guang Lei, Chao Mao, Amber D Horbath, Yuelong Yan, Shirong Cai, Yao Jun, Yan Jiang, Mingchuang Sun, Xiaoguang Liu, Jun Cheng, Zhihao Xu, Hyemin Lee, Qidong Li, Zhengze Lu, Li Zhuang, Mei-Kuang Chen, Anagha Alapati, Timothy Anthony Yap, Mien-Chie Hung, Mingjian James You, Helen Piwnica-Worms, Boyi Gan
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer discovery 14 (8) (2024)
Weigang Dai, Yinan Liu, Tianhao Zhang, Zhixin Huang, Xiang Xu, Zeyu Zhao, Jianqiu Liu, Ertao Zhai, Shirong Cai, Jianhui Chen
Spindle function and Wnt pathway inhibition by PBX1 to suppress tumor progression via downregulating DCDC2 in colorectal cancer. Oncogenesis 12 (1) (2023)
Michael C Heinrich, Xinhua Zhang, Robin L Jones, Suzanne George, Cesar Serrano, Yan-Hong Deng, Sebastian Bauer, Shirong Cai, Xin Wu, Yongjian Zhou, Kaixiong Tao, Zhi-Chao Zheng, Jun Zhang, Yuehong Cui, Hui Cao, Meining Wang, Jin Hu, Jason Yang, Jian Li, Lin Shen
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Weigang Dai, Yinan Liu, Tianhao Zhang, Zhixin Huang, Xiang Xu, Zeyu Zhao, Jianqiu Liu, Ertao Zhai, Shirong Cai, Jianhui Chen
Spindle function and Wnt pathway inhibition by PBX1 to suppress tumor progression via downregulating DCDC2 in colorectal cancer. Oncogenesis 12 (1) (2023)
Weigang Dai, Yinan Liu, Tianhao Zhang, Zhixin Huang, Xiang Xu, Zeyu Zhao, Jianqiu Liu, Ertao Zhai, Shirong Cai, Jianhui Chen
Spindle function and Wnt pathway inhibition by PBX1 to suppress tumor progression via downregulating DCDC2 in colorectal cancer. Oncogenesis 12 (1) (2023)
Jian Li, Shirong Cai, Yongjian Zhou, Jun Zhang, Ye Zhou, Hui Cao, Xin Wu, Yanhong Deng, Zhao Huang, Juan Dong, Lin Shen
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)